These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26631934)

  • 1. Robust estimation of the proportion of treatment effect explained by surrogate marker information.
    Parast L; McDermott MM; Tian L
    Stat Med; 2016 May; 35(10):1637-53. PubMed ID: 26631934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating surrogate marker information using censored data.
    Parast L; Cai T; Tian L
    Stat Med; 2017 May; 36(11):1767-1782. PubMed ID: 28088843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a surrogate marker for early testing of a treatment effect.
    Parast L; Cai T; Tian L
    Biometrics; 2019 Dec; 75(4):1253-1263. PubMed ID: 31009073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust methods to correct for measurement error when evaluating a surrogate marker.
    Parast L; Garcia TP; Prentice RL; Carroll RJ
    Biometrics; 2022 Mar; 78(1):9-23. PubMed ID: 33021738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.
    Zhou RR; Zhao SD; Parast L
    Stat Med; 2022 May; 41(12):2227-2246. PubMed ID: 35189671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible evaluation of surrogate markers with Bayesian model averaging.
    Duan Y; Parast L
    Stat Med; 2024 Feb; 43(4):774-792. PubMed ID: 38081586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the value of a censored surrogate outcome.
    Parast L; Tian L; Cai T
    Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing for heterogeneity in the utility of a surrogate marker.
    Parast L; Cai T; Tian L
    Biometrics; 2023 Jun; 79(2):799-810. PubMed ID: 34874550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker.
    Wang X; Parast L; Tian LU; Cai T
    Biometrika; 2020 Mar; 107(1):107-122. PubMed ID: 32587413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating multiple surrogate markers with censored data.
    Parast L; Cai T; Tian L
    Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust approach to combining multiple markers to improve surrogacy.
    Wang X; Parast L; Han L; Tian L; Cai T
    Biometrics; 2023 Jun; 79(2):788-798. PubMed ID: 35426444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of longitudinal surrogate markers.
    Agniel D; Parast L
    Biometrics; 2021 Jun; 77(2):477-489. PubMed ID: 32506496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doubly robust evaluation of high-dimensional surrogate markers.
    Agniel D; Hejblum BP; Thiébaut R; Parast L
    Biostatistics; 2023 Oct; 24(4):985-999. PubMed ID: 35791753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An entropy-based nonparametric test for the validation of surrogate endpoints.
    Miao X; Wang YC; Gangopadhyay A
    Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a surrogate with heterogeneous utility to test for a treatment effect.
    Parast L; Cai T; Tian L
    Stat Med; 2023 Jan; 42(1):68-88. PubMed ID: 36372072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing heterogeneity in surrogacy using censored data.
    Parast L; Tian L; Cai T
    Stat Med; 2024 Jul; 43(17):3184-3209. PubMed ID: 38812276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A measure of the proportion of treatment effect explained by a surrogate marker.
    Wang Y; Taylor JM
    Biometrics; 2002 Dec; 58(4):803-12. PubMed ID: 12495134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counterfactual links to the proportion of treatment effect explained by a surrogate marker.
    Taylor JM; Wang Y; Thiébaut R
    Biometrics; 2005 Dec; 61(4):1102-11. PubMed ID: 16401284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying surrogate markers in real-world comparative effectiveness research.
    Han L; Wang X; Cai T
    Stat Med; 2022 Nov; 41(26):5290-5304. PubMed ID: 36062392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
    Wang X; Cai T; Tian L; Bourgeois F; Parast L
    Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.